C-Peptide in Beta Cell Regeneration and Autoimmune Diabetes: A Therapeutic Perspective

References

1. LiuJ. TingJ.P. Al-AzzamS. DingY. AfsharS. Therapeutic advances in diabetes, autoimmune, and neurological diseases.Int. J. Mol. Sci.2021226280510.3390/ijms2206280533802091
   [Google Scholar]
2. HedeskovC.J. Mechanism of glucose-induced insulin secretion.Physiol. Rev.198060244250910.1152/physrev.1980.60.2.4426247727
   [Google Scholar]
3. SzablewskiL. Role of immune system in type 1 diabetes mellitus pathogenesis.Int. Immunopharmacol.201422118219110.1016/j.intimp.2014.06.03324993340
   [Google Scholar]
4. BolliG.B. FanelliC.G. Physiology of glucose counterregulation to hypoglycemia.Endocrinol. Metab. Clin. North Am.199928346749310.1016/S0889‑8529(05)70083‑910500926
   [Google Scholar]
5. AnnicchiaricoA. BarileB. BuccolieroC. NicchiaG.P. BrunettiG. Alternative therapeutic strategies in diabetes management.World J. Diabetes20241561142116110.4239/wjd.v15.i6.114238983831
   [Google Scholar]
6. MaddaloniE. BolliG.B. FrierB.M. LittleR.R. LeslieR.D. PozzilliP. BuzzettiR. C‐peptide determination in the diagnosis of type of diabetes and its management: A clinical perspective.Diabetes Obes. Metab.202224101912192610.1111/dom.1478535676794
   [Google Scholar]
7. WahrenJ. EkbergK. JörnvallH. C-peptide is a bioactive peptide.Diabetologia200750350350910.1007/s00125‑006‑0559‑y17235526
   [Google Scholar]
8. SimB.C. KangY.E. YouS.K. LeeS.E. NgaH.T. LeeH.Y. NguyenT.L. MoonJ.S. TianJ. JangH.J. LeeJ.E. YiH.S. Hepatic T-cell senescence and exhaustion are implicated in the progression of fatty liver disease in patients with type 2 diabetes and mouse model with nonalcoholic steatohepatitis.Cell Death Dis.202314961810.1038/s41419‑023‑06146‑837735474
   [Google Scholar]
9. JonesA.G. HattersleyA.T. The clinical utility of C‐peptide measurement in the care of patients with diabetes.Diabet. Med.201330780381710.1111/dme.1215923413806
   [Google Scholar]
10. SteinerD.F. The proinsulin C-peptide--A multirole model.Exp. Diabesity Res.20045171410.1080/1543860049042438915198367
    [Google Scholar]
11. MayerJ.P. ZhangF. DiMarchiR.D. Insulin structure and function.Biopolymers200788568771310.1002/bip.2073417410596
    [Google Scholar]
12. LuziL. ZerbiniG. CaumoA. C-peptide: A redundant relative of insulin?Diabetologia200750350050210.1007/s00125‑006‑0576‑x17225123
    [Google Scholar]
13. SimmondsM.J. DetterichJ.A. ConnesP. DetterichJ.A. ConnesP. Nitric oxide, vasodilation and the red blood cell.Biorheology2014512-312113410.3233/BIR‑14065324819865
    [Google Scholar]
14. BrandenburgD. History and diagnostic significance of C-peptide.J. Diabetes Res.20082008157686210.1155/2008/57686218509495
    [Google Scholar]
15. RoepB.O. ThomaidouS. van TienhovenR. ZaldumbideA. Type 1 diabetes mellitus as a disease of the β-cell (do not blame the immune system?).Nat. Rev. Endocrinol.202117315016110.1038/s41574‑020‑00443‑433293704
    [Google Scholar]
16. GanM.J. Albanese-O’NeillA. HallerM.J. Type 1 diabetes: Current concepts in epidemiology, pathophysiology, clinical care, and research.Curr. Probl. Pediatr. Adolesc. Health Care2012421026929110.1016/j.cppeds.2012.07.00223046732
    [Google Scholar]
17. TruccoM. Regeneration of the pancreatic β cell.J. Clin. Invest.2005115151210.1172/JCI20052393515630433
    [Google Scholar]
18. ChistyakovaO.V. Signaling pathway of insulin and insulin-like growth factor 1 (IGF-1) as a potential regulator of lifespan.J. Evol. Biochem. Physiol.200844111110.1134/S0022093008010015
    [Google Scholar]
19. MillmanJ.R. PagliucaF.W. Autologous pluripotent stem cell–derived β-like cells for diabetes cellular therapy.Diabetes20176651111112010.2337/db16‑140628507211
    [Google Scholar]
20. FiorinaP. VoltarelliJ. ZavazavaN. Immunological applications of stem cells in type 1 diabetes.Endocr. Rev.201132672575410.1210/er.2011‑000821862682
    [Google Scholar]
21. BouwensL. RoomanI. Regulation of pancreatic beta-cell mass.Physiol. Rev.20058541255127010.1152/physrev.00025.200416183912
    [Google Scholar]
22. NewsholmeP. KeaneK.N. CarlessiR. CruzatV. Oxidative stress pathways in pancreatic β-cells and insulin-sensitive cells and tissues: Importance to cell metabolism, function, and dysfunction.Am. J. Physiol. Cell Physiol.20193173C420C43310.1152/ajpcell.00141.201931216193
    [Google Scholar]
23. LuppiP. DrainP. C‐peptide antioxidant adaptive pathways in β cells and diabetes.J. Intern. Med.2017281172410.1111/joim.1252227251308
    [Google Scholar]
24. LiuY. Delivery of a pancreatic beta cell-derived hormone to erythrocytes by albumin and downstream cellular effects.Michigan State University2015
    [Google Scholar]
25. LuppiP. CifarelliV. TseH. PiganelliJ. TruccoM. Human C-peptide antagonises high glucose-induced endothelial dysfunction through the nuclear factor-κB pathway.Diabetologia20085181534154310.1007/s00125‑008‑1032‑x18493738
    [Google Scholar]
26. ShpakovA.O. Mechanisms of action and therapeutic potential of proinsulin C-peptide.J. Evol. Biochem. Physiol.201753318019010.1134/S0022093017030024
    [Google Scholar]
27. MziautH. HennigerG. GanssK. HempelS. WolkS. McChordJ. ChowdhuryK. RavassardP. KnochK.P. KrautzC. WeitzJ. GrützmannR. PilarskyC. SolimenaM. KerstingS. MiR-132 controls pancreatic beta cell proliferation and survival through Pten/AKT/Foxo3 signaling.Mol. Metab.20203115016210.1016/j.molmet.2019.11.01231918917
    [Google Scholar]
28. PinheiroM.M. PinheiroF.M.M. DinizS.N. FabbriA. InfanteM. Combination of vitamin D and dipeptidyl peptidase-4 inhibitors (VIDPP-4i) as an immunomodulation therapy for autoimmune diabetes.Int. Immunopharmacol.20219510751810.1016/j.intimp.2021.10751833756226
    [Google Scholar]
29. BurrackA.L. MartinovT. FifeB.T. T cell-mediated beta cell destruction: Autoimmunity and alloimmunity in the context of type 1 diabetes.Front. Endocrinol.2017834310.3389/fendo.2017.0034329259578
    [Google Scholar]
30. ChanJ. S.; Steiner, D.F. Insulin through the ages: Phylogeny of a growth promoting and metabolic regulatory hormone.Am. Zool.200040221322210.1093/icb/40.2.213
    [Google Scholar]
31. LewittM.S. BoydG.W. Role of the insulin-like growth factor system in neurodegenerative disease.Int. J. Mol. Sci.2024258451210.3390/ijms2508451238674097
    [Google Scholar]
32. LuoJ. JiangJ. HuangH. JiangF. XuZ. ZhouZ. ZhuH. C-peptide ameliorates high glucose-induced podocyte dysfunction through the regulation of the Notch and TGF-β signaling pathways.Peptides202114217055710.1016/j.peptides.2021.17055733901627
    [Google Scholar]
33. AlmaçaJ. CaicedoA. LandsmanL. Beta cell dysfunction in diabetes: The islet microenvironment as an unusual suspect.Diabetologia202063102076208510.1007/s00125‑020‑05186‑532894318
    [Google Scholar]
34. DruckerD.J. Glucagon-like peptide-1 and the islet β-cell: Augmentation of cell proliferation and inhibition of apoptosis.Endocrinology2003144125145514810.1210/en.2003‑114714645210
    [Google Scholar]
35. DerkachK.V. BakhtyukovA.A. BasovaN.E. ZorinaI.I. ShpakovA.O. The restorative effect of combined insulin and C-peptide intranasal administration on hormonal status and hypothalamic signaling in the male rat model of severe short-term streptozotocin-induced diabetes.J. Evol. Biochem. Physiol.202258367769110.1134/S002209302203005X
    [Google Scholar]
36. FuZ. GilbertE.R. LiuD. Regulation of insulin synthesis and secretion and pancreatic beta-cell dysfunction in diabetes.Curr. Diabetes Rev.201391255310.2174/15733991380414322522974359
    [Google Scholar]
37. ZhangY. GaoY. WangJ. GaoR. SuQ. ZhangJ. JiangL. ZhangC. HuangP. WangW. FengZ. Bioenergetic metabolism modulatory peptide hydrogel for cardiac protection and repair after myocardial infarction.Adv. Funct. Mater.20243424231277210.1002/adfm.202312772
    [Google Scholar]
38. GhaniM.W. YeL. YiZ. GhaniH. BirmaniM.W. NawabA. CunL.G. BinL. MeiX. Pancreatic β-cell replacement: Advances in protocols used for differentiation of pancreatic progenitors to β-like cells.Folia Histochem. Cytobiol.201957310111531396945
    [Google Scholar]
39. HaidetJ. CifarelliV. TruccoM. LuppiP. Anti-inflammatory properties of C-Peptide.Rev. Diabet. Stud.20096316817910.1900/RDS.2009.6.16820039006
    [Google Scholar]
40. YostenG.L.C. Maric-BilkanC. LuppiP. WahrenJ. Physiological effects and therapeutic potential of proinsulin C-peptide.Am. J. Physiol. Endocrinol. Metab.201430711E955E96810.1152/ajpendo.00130.201425249503
    [Google Scholar]
41. PathakV. PathakN.M. O’NeillC.L. Guduric-FuchsJ. MedinaR.J. Therapies for type 1 diabetes: Current scenario and future perspectives.Clin. Med. Insights Endocrinol. Diabetes201912117955141984452110.1177/117955141984452131105434
    [Google Scholar]
42. BasileG. QadirM.M.F. Mauvais-JarvisF. VetereA. ShobaV. ModellA.E. PastoriR.L. RussH.A. WagnerB.K. Dominguez-BendalaJ. Emerging diabetes therapies: Bringing back the β-cells.Mol. Metab.20226010147710.1016/j.molmet.2022.10147735331962
    [Google Scholar]
43. CnopM. WelshN. JonasJ.C. JörnsA. LenzenS. EizirikD.L. Mechanisms of pancreatic β-cell death in type 1 and type 2 diabetes: many differences, few similarities.Diabetes200554S97S10710.2337/diabetes.54.suppl_2.S9716306347
    [Google Scholar]
44. LiY. SunF. YueT.T. WangF.X. YangC.L. LuoJ.H. RongS.J. XiongF. ZhangS. WangC.Y. Revisiting the antigen-presenting function of β cells in T1D pathogenesis.Front. Immunol.20211269078310.3389/fimmu.2021.69078334335595
    [Google Scholar]
45. HuangQ. ZhuJ. Regulatory T cell-based therapy in type 1 diabetes: Latest breakthroughs and evidence.Int. Immunopharmacol.202414011272410.1016/j.intimp.2024.11272439098233
    [Google Scholar]
46. VerhaegheJ. LoosR. VlietinckR. Van HerckE. Van BreeR. De SchutterA.M. C-peptide, insulin-like growth factors I and II, and insulin-like growth factor binding protein-1 in cord serum of twins: Genetic versus environmental regulation.Int. J. Gynaecol. Obstet.199756330830910.1016/S0020‑7292(97)83416‑9
    [Google Scholar]
47. CifarelliV. TruccoM. LuppiP. Anti-inflammatory effects of C-peptide prevent endothelial dysfunction in type 1 diabetes.Immunol. Endocr. Metab. Agents Med. Chem.20111115970
    [Google Scholar]
48. LuppiP. DrainP. Autocrine C‐peptide mechanism underlying INS1 beta cell adaptation to oxidative stress.Diabetes Metab. Res. Rev.201430759960910.1002/dmrr.252824459093
    [Google Scholar]
49. Marek-TrzonkowskaN. MyśliwecM. SiebertJ. TrzonkowskiP. Clinical application of regulatory T cells in type 1 diabetes.Pediatr. Diabetes201314532233210.1111/pedi.1202923627860
    [Google Scholar]
50. PhamM.N. KolbH. BattelinoT. LudvigssonJ. PozzilliP. ZiveheF. RodenM. Mandrup-PoulsenT. SchlootN.C. Fasting and meal-stimulated residual beta cell function is positively associated with serum concentrations of proinflammatory cytokines and negatively associated with anti-inflammatory and regulatory cytokines in patients with longer term type 1 diabetes.Diabetologia20135661356136310.1007/s00125‑013‑2883‑323494449
    [Google Scholar]
51. ChenJ. HuangY. LiuC. ChiJ. WangY. XuL. The role of C-peptide in diabetes and its complications: An updated review.Front. Endocrinol.202314125609310.3389/fendo.2023.125609337745697
    [Google Scholar]
52. KondělkováK. VokurkováD. KrejsekJ. BorskáL. FialaZ. AndrýsC. Regulatory T cells (TREG) and their roles in immune system with respect to immunopathological disorders.Acta Med.2010532737710.14712/18059694.2016.6320672742
    [Google Scholar]
53. EizirikD.L. SzymczakF. MalloneR. Why does the immune system destroy pancreatic β-cells but not α-cells in type 1 diabetes?Nat. Rev. Endocrinol.202319742543410.1038/s41574‑023‑00826‑337072614
    [Google Scholar]
54. SmithT.J. Insulin-like growth factor-I regulation of immune function: A potential therapeutic target in autoimmune diseases?Pharmacol. Rev.201062219923610.1124/pr.109.00246920392809
    [Google Scholar]
55. BoS. GentileL. CastiglioneA. PrandiV. CanilS. GhigoE. CicconeG. C-peptide and the risk for incident complications and mortality in type 2 diabetic patients: A retrospective cohort study after a 14-year follow-up.Eur. J. Endocrinol.2012167217318010.1530/EJE‑12‑008522577110
    [Google Scholar]
56. KwiatkowskiA.J. StewartJ.M. ChoJ.J. AvramD. KeselowskyB.G. Nano and microparticle emerging strategies for treatment of autoimmune diseases: multiple sclerosis and type 1 diabetes.Adv. Healthc. Mater.2020911200016410.1002/adhm.20200016432519501
    [Google Scholar]
57. MuscogiuriG. CaporussoM. CarusoP. PoggiC.D. VitaleM. ZurruA. ColaoA. Current evidence on gender-related risk factors for type 1 diabetes, type 2 diabetes and prediabetes: A reappraisal of the Italian study group on gender difference in endocrine diseases.J. Endocrinol. Invest.202448357358510.1007/s40618‑024‑02491‑339570488
    [Google Scholar]
58. NilssonB. TeramuraY. EkdahlK.N. The role and regulation of complement activation as part of the thromboinflammation elicited in cell therapies.Mol. Immunol.201461218519010.1016/j.molimm.2014.06.00924998801
    [Google Scholar]
59. SchuerweghA.J. DombrechtE.J. StevensW.J. Van OffelJ.F. BridtsC.H. De ClerckL.S. Influence of pro-inflammatory (IL-1α, IL-6, TNF-α, IFN-γ) and anti-inflammatory (IL-4) cytokines on chondrocyte function.Osteoarthritis Cartilage200311968168710.1016/S1063‑4584(03)00156‑012954239
    [Google Scholar]
60. KhodabandehlooH. Gorgani-FiruzjaeeS. PanahiG. MeshkaniR. Molecular and cellular mechanisms linking inflammation to insulin resistance and β-cell dysfunction.Transl. Res.2016167122825610.1016/j.trsl.2015.08.01126408801
    [Google Scholar]
61. PoteryaevaO.N. UsyninI.F. Molecular mechanisms of action and physiological effects of the proinsulin C-peptide (a systematic review). Biochem.Moscow Suppl Ser B202115273910.1134/S1990750821010066
    [Google Scholar]
62. WashburnR.L. MuellerK. KaurG. MorenoT. Moustaid-MoussaN. RamalingamL. DufourJ.M. C-peptide as a therapy for type 1 diabetes mellitus.Biomedicines20219327010.3390/biomedicines903027033800470
    [Google Scholar]
63. HaidetJ CifarelliV GengX TruccoM LuppiP. C-peptide: a new molecule with anti-inflammatory properties.201211112710.1007/978‑1‑61779‑391‑2_10
    [Google Scholar]
64. SaishoY. Postprandial C-peptide to glucose ratio as a marker of β cell function: Implication for the management of type 2 diabetes.Int. J. Mol. Sci.201617574410.3390/ijms1705074427196896
    [Google Scholar]
65. Jamiołkowska-SztabkowskaM. Głowińska-OlszewskaB. BossowskiA. C-peptide and residual β-cell function in pediatric diabetes – state of the art.Pediatr. Endocrinol. Diabetes Metab.202127212313310.5114/pedm.2021.10716534514768
    [Google Scholar]
66. DobretsovM. RomanovskyD. StimersJ.R. Early diabetic neuropathy: Triggers and mechanisms.World J. Gastroenterol.200713217519110.3748/wjg.v13.i2.17517226897
    [Google Scholar]
67. JohanssonB.L. KernellA. SjöbergS. WahrenJ. Influence of combined C-peptide and insulin administration on renal function and metabolic control in diabetes type 1.J. Clin. Endocrinol. Metab.19937749769818408474
    [Google Scholar]
68. LinK.J. WangT.J. ChenS.D. LinK.L. LiouC.W. LanM.Y. ChuangY.C. ChuangJ.H. WangP.W. LeeJ.J. WangF.S. LinH.Y. LinT.K. Two birds one stone: The neuroprotective effect of antidiabetic agents on Parkinson disease—focus on sodium-glucose cotransporter 2 (SGLT2) inhibitors.Antioxidants20211012193510.3390/antiox1012193534943038
    [Google Scholar]
69. LachinJ.M. McGeeP. PalmerJ.P. Impact of C-peptide preservation on metabolic and clinical outcomes in the diabetes control and complications trial.Diabetes201463273974810.2337/db13‑088124089509
    [Google Scholar]
70. BhattacharyaS. ParaskarG. JhaM. GuptaG.L. PrajapatiB.G. Deciphering regulatory T-cell dynamics in cancer immunotherapy: Mechanisms, implications, and therapeutic innovations.ACS Pharmacol. Transl. Sci.2024782215223610.1021/acsptsci.4c0015639144553
    [Google Scholar]
71. PolonskyK.S. Lilly lecture 1994. The β-cell in diabetes: From molecular genetics to clinical research.Diabetes199544670571710.2337/diab.44.6.7057789637
    [Google Scholar]
72. Nordin-JohanssonA. AsplundK. Randomized controlled trials and consensus as a basis for interventions in internal medicine.J. Intern. Med.200024719410410.1046/j.1365‑2796.2000.00583.x10672136
    [Google Scholar]
73. WahrenJ. KallasÅ. SimaA.A. The clinical potential of C-peptide replacement in type 1 diabetes.Diabetes2012614761772
    [Google Scholar]
74. SjöbergL. PitkäniemiJ. HaapalaL. KaajaR. TuomilehtoJ. Fertility in people with childhood-onset type 1 diabetes.Diabetologia2013561788110.1007/s00125‑012‑2731‑x23011355
    [Google Scholar]
75. ZieglerR. HeidtmannB. HilgardD. HoferS. RosenbauerJ. HollR. Frequency of SMBG correlates with HbA1c and acute complications in children and adolescents with type 1 diabetes.Pediatr. Diabetes2011121111710.1111/j.1399‑5448.2010.00650.x20337978
    [Google Scholar]
76. ForstT. HanefeldM. JacobS. MoeserG. SchwenkG. PfütznerA. HauptA. Association of sulphonylurea treatment with all-cause and cardiovascular mortality: A systematic review and meta-analysis of observational studies.Diab. Vasc. Dis. Res.201310430231410.1177/147916411246544223291340
    [Google Scholar]
77. WahrenJ. LarssonC. C-peptide: New findings and therapeutic possibilities.Diabetes Res. Clin. Pract.2015107330931910.1016/j.diabres.2015.01.01625648391
    [Google Scholar]
78. CarlbomL. EspesD. LubberinkM. ErikssonO. JohanssonL. JanssonL. KorsgrenO. AhlströmH. CarlssonP.O. Pancreatic perfusion and subsequent response to glucose in healthy individuals and patients with type 1 diabetes.Diabetologia20165991968197210.1007/s00125‑016‑4016‑227306617
    [Google Scholar]
79. TianJ. DangH. O’LacoK.A. SongM. TiuB.C. GillesS. ZakarianC. KaufmanD.L. Homotaurine treatment enhances CD4+ and CD8+ regulatory T cell responses and synergizes with low-dose anti-CD3 to enhance diabetes remission in type 1 diabetic mice.Immunohorizons201931049851010.4049/immunohorizons.190001931636084
    [Google Scholar]
80. GibbF.W. McKnightJ.A. ClarkeC. StrachanM.W.J. Preserved C-peptide secretion is associated with fewer low-glucose events and lower glucose variability on flash glucose monitoring in adults with type 1 diabetes.Diabetologia202063590691410.1007/s00125‑020‑05099‑332034440
    [Google Scholar]